Understanding Adverse Effects Associated With Immune-Based Combination Therapies for Metastatic Renal Cell Carcinoma
A meta-analysis of phase 3 randomized control trials sought to identify the TRAEs associated with 7 therapeutic regimens for the treatment of mRCC.